Restricted accessResearch articleFirst published online 2017-02
Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity
The interaction between podoplanin (PDPN) and C-type lectin-like receptor 2 (CLEC-2) is involved in tumor malignancy. We have established many monoclonal antibodies (mAbs) against human podoplanin using the cancer-specific mAb (CasMab) technology. LpMab-21, one of the mouse antipodoplanin mAbs, is of the IgG2a subclass, and its minimum epitope was determined to be Thr76–Arg79 of the human podoplanin. Importantly, sialic acid is linked to Thr76; therefore, LpMab-21 is an antiglycopeptide mAb (GpMab). In this study, we investigated whether LpMab-21 shows antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against human podoplanin-expressing cancer cell lines in vitro and also studied its antitumor activities using a xenograft model. LpMab-21 showed high ADCC and CDC activities against not only podoplanin-expressing Chinese hamster ovary cells but also LN319 glioblastoma cells and PC-10 lung cancer cells, both of which endogenously express podoplanin. Furthermore, LpMab-21 decreased tumor growth in vivo, indicating that LpMab-21 could be useful for antibody therapy against human podoplanin-expressing cancers.
Get full access to this article
View all access options for this article.
References
1.
Martin-VillarE, SchollFG, GamalloC, YurritaMM, Munoz-GuerraM, CrucesJ, and QuintanillaM: Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer, 2005; 113:899–910.
2.
YuanP, TemamS, El-NaggarA, ZhouX, LiuD, LeeJ, and MaoL: Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer, 2006; 107:563–569.
3.
TakagiS, Oh-haraT, SatoS, GongB, TakamiM, and FujitaN: Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis. Int J Cancer, 2014; 134:2605–2614.
4.
KunitaA, KashimaTG, OhazamaA, GrigoriadisAE, and FukayamaM: Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. Am J Pathol, 2011; 179:1041–1049.
5.
ChandramohanV, BaoX, Kato KanekoM, KatoY, KeirST, SzafranskiSE, KuanCT, PastanIH, and BignerDD: Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int J Cancer, 2013; 132:2339–2348.
6.
KatoY, KanekoMK, KunoA, UchiyamaN, AmanoK, ChibaY, HasegawaY, HirabayashiJ, NarimatsuH, MishimaK, and OsawaM: Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun, 2006; 349:1301–1307.
7.
MishimaK, KatoY, KanekoMK, NakazawaY, KunitaA, FujitaN, TsuruoT, NishikawaR, HiroseT, and MatsutaniM: Podoplanin expression in primary central nervous system germ cell tumors: A useful histological marker for the diagnosis of germinoma. Acta Neuropathol (Berl), 2006; 111:563–568.
8.
MishimaK, KatoY, KanekoMK, NishikawaR, HiroseT, and MatsutaniM: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol (Berl), 2006; 111:483–488.
9.
AbeS, MoritaY, KanekoMK, HanibuchiM, TsujimotoY, GotoH, KakiuchiS, AonoY, HuangJ, SatoS, KishukuM, TaniguchiY, AzumaM, KawazoeK, SekidoY, YanoS, AkiyamaS, SoneS, MinakuchiK, KatoY, and NishiokaY: A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol, 2013; 190:6239–6249.
10.
KatoY, VaidyanathanG, KanekoMK, MishimaK, SrivastavaN, ChandramohanV, PegramC, KeirST, KuanCT, BignerDD, and ZalutskyMR: Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl Med Biol, 2010; 37:785–794.
11.
KatoY, FujitaN, KunitaA, SatoS, KanekoM, OsawaM, TsuruoT: Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem, 2003; 278:51599–51605.
12.
KatoY, SasagawaI, KanekoM, OsawaM, FujitaN, and TsuruoT: Aggrus: A diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene, 2004; 23:8552–8556.
13.
KatoY, KanekoM, SataM, FujitaN, TsuruoT, and OsawaM: Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol, 2005; 26:195–200.
14.
KunitaA, KashimaTG, MorishitaY, FukayamaM, KatoY, TsuruoT, and FujitaN: The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol, 2007; 170:1337–1347.
15.
KanekoMK, KatoY, KitanoT, and OsawaM: Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene, 2006; 378:52–57.
16.
PulaB, JethonA, PiotrowskaA, GomulkiewiczA, OwczarekT, CalikJ, WojnarA, WitkiewiczW, RysJ, UgorskiM, DziegielP, and Podhorska-OkolowM: Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. Histopathology, 2011; 59:1249–1260.
17.
KawaseA, IshiiG, NagaiK, ItoT, NaganoT, MurataY, HishidaT, NishimuraM, YoshidaJ, SuzukiK, and OchiaiA: Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer, 2008; 123:1053–1059.
18.
HoshinoA, IshiiG, ItoT, AoyagiK, OhtakiY, NagaiK, SasakiH, and OchiaiA: Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: Podoplanin in fibroblast functions for tumor progression. Cancer Res, 2011; 71:4769–4779.
19.
SchoppmannSF, JeschB, RieglerMF, MaroskeF, SchwameisK, JomrichG, and BirnerP: Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. Clin Exp Metastasis, 2013; 30:441–446.
20.
ShindoK, AishimaS, OhuchidaK, FujiwaraK, FujinoM, MizuuchiY, HattoriM, MizumotoK, TanakaM, and OdaY: Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. Mol Cancer, 2013; 12:168.
21.
InoueH, TsuchiyaH, MiyazakiY, KikuchiK, IdeF, SakashitaH, and KusamaK: Podoplanin expressing cancer-associated fibroblasts in oral cancer. Tumour Biol, 2014; 35:11345–11352.
22.
Suzuki-InoueK, KatoY, InoueO, KanekoMK, MishimaK, YatomiY, YamazakiY, NarimatsuH, and OzakiY: Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem, 2007; 282:25993–26001.
23.
KatoY, KanekoMK, KunitaA, ItoH, KameyamaA, OgasawaraS, MatsuuraN, HasegawaY, Suzuki-InoueK, InoueO, OzakiY, and NarimatsuH: Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci, 2008; 99:54–61.
24.
NagaeM, Morita-MatsumotoK, KatoM, KanekoMK, KatoY, and YamaguchiY: A Platform of C-Type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin. Structure, 2014; 22:1711–1721.
25.
OgasawaraS, KanekoMK, PriceJE, and KatoY: Characterization of anti-podoplanin monoclonal antibodies: Critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma, 2008; 27:259–267.
26.
TakagiS, SatoS, Oh-haraT, TakamiM, KoikeS, MishimaY, HatakeK, and FujitaN: Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS One, 2013; 8:e73609.
27.
NakazawaY, TakagiS, SatoS, Oh-haraT, KoikeS, TakamiM, AraiH, and FujitaN: Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies. Cancer Sci, 2011; 102:2051–2057.
28.
MarksA, SutherlandDR, BaileyD, IglesiasJ, LawJ, LeiM, YegerH, BanerjeeD, and BaumalR: Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer, 1999; 80:569–578.
29.
KonoT, ShimodaM, TakahashiM, MatsumotoK, YoshimotoT, MizutaniM, TabataC, OkoshiK, WadaH, and KuboH: Immunohistochemical detection of the lymphatic marker podoplanin in diverse types of human cancer cells using a novel antibody. Int J Oncol, 2007; 31:501–508.
30.
KatoY, and KanekoMK: A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep, 2014; 4:5924.
31.
KanekoMK, OkiH, HozumiY, LiuX, OgasawaraS, TakagiM, GotoK, and KatoY: Monoclonal antibody LpMab-9 recognizes O-glycosylated N-terminus of human podoplanin. Monoclon Antib Immunodiagn Immunother, 2015; 34:310–317.
KatoY, KunitaA, AbeS, OgasawaraS, FujiiY, OkiH, FukayamaM, NishiokaY, and KanekoMK: The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. Oncotarget, 2015; 6:36003–36018.
34.
OgasawaraS, OkiH, KanekoMK, HozumiY, LiuX, HonmaR, FujiiY, NakamuraT, GotoK, TakagiM, and KatoY: Development of monoclonal antibody LpMab-10 recognizing non-glycosylated PLAG1/2 domain including Thr34 of human podoplanin. Monoclon Antib Immunodiagn Immunother, 2015; 34:318–326.
35.
OkiH, KanekoMK, OgasawaraS, TsujimotoY, LiuX, SugawaraM, TakakuboY, TakagiM, and KatoY: Characterization of a monoclonal antibody LpMab-7 recognizing non-PLAG domain of podoplanin. Monoclon Antib Immunodiagn Immunother, 2015; 34:174–180.
36.
OkiH, OgasawaraS, KanekoMK, TakagiM, YamauchiM, and KatoY: Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin. Monoclon Antib Immunodiagn Immunother, 2015; 34:44–50.
37.
KatoY, OgasawaraS, OkiH, GoichbergP, HonmaR, FujiiY, and KanekoMK: LpMab-12 established by CasMab technology specifically detects sialylated O-Glycan on Thr52 of platelet aggregation-stimulating domain of human podoplanin. PLoS One, 2016; 11:e0152912.
38.
KatoY, OgasawaraS, OkiH, HonmaR, TakagiM, FujiiY, NakamuraT, SaidohN, KannoH, UmetsuM, KamataS, KuboH, YamadaM, SawaY, MoritaK, HaradaH, SuzukiH, and KanekoMK: Novel monoclonal antibody LpMab-17 developed by CasMab technology distinguishes human podoplanin from monkey podoplanin. Monoclon Antib Immunodiagn Immunother, 2016; 35:109–116.
39.
OgasawaraS, KanekoMK, HonmaR, OkiH, FujiiY, TakagiM, SuzukiH, and KatoY: Establishment of mouse monoclonal antibody LpMab-13 against human podoplanin. Monoclon Antib Immunodiagn Immunother, 2016 [Epub ahead of print]; DOI: 10.1089/mab.2016.0006.rev.
40.
KanekoMK, NakamuraT, HonmaR, OgasawaraS, FujiiY, AbeS, TakagiM, HaradaH, SuzukiH, NishiokaY, and KatoY: Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. Cancer Med, 2016. In press. DOI: 10.1002/cam4.954
41.
AbdelmoulaM, SpertiniF, ShibataT, GyotokuY, LuzuyS, LambertPH, and IzuiS: IgG3 is the major source of cryoglobulins in mice. J Immunol, 1989; 143:526–532.
42.
OkiH, HonmaR, OgasawaraS, FujiiY, LiuX, KanekoM, TakagiM, and KatoY: Development of a sensitive monoclonal antibody PMab-2 against rat podoplanin. Monoclon Antib Immunodiagn Immunother, 2015; 34:396–403.
43.
KanekoMK, KunitaA, AbeS, TsujimotoY, FukayamaM, GotoK, SawaY, NishiokaY, and KatoY: Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci, 2012; 103:1913–1919.
44.
ShibataT, UchidaH, ShiroyamaT, OkuboY, SuzukiT, IkedaH, YamaguchiM, MiyagawaY, FukuharaT, CohenJB, GloriosoJC, WatabeT, HamadaH, and TaharaH: Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread. Gene Ther, 2016; 23:479–488.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
